Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs



Status:Recruiting
Conditions:Blood Cancer, Blood Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/23/2018
Start Date:October 2016
End Date:June 2020
Contact:Harold Keer, MD, PhD
Email:harold.keer@astx.com
Phone:925-719-0741

Use our guide to learn which trials are right for you!

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents

A Phase 3, randomized, open-label, parallel-group, multicenter study designed to evaluate the
efficacy and safety of guadecitabine in subjects with MDS or CMML who failed or relapsed
after adequate prior treatment with azacitidine, decitabine, or both. This global study will
be conducted in approximately 15 countries. Approximately 408 subjects from approximately 100
study centers will be randomly assigned in a 2:1 ratio to either guadecitabine (approximately
272 subjects) or Treatment Choice (approximately 136 subjects). The study consists of a
14-day screening period, a treatment period, a safety follow-up visit, and a long-term
follow-up period. The study is expected to last more than 2 years, and the duration of
individual subject participation will vary. Subjects may continue to receive treatment for as
long as they continue to benefit.

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs Treatment
Choice (TC). Approximately 408 subjects will be randomly assigned 2:1 to either guadecitabine
or TC.

- Guadecitabine: approximately 272 subjects.

- TC: approximately 136 subjects.

Before randomization, the investigator will assign each subject to one of the following TC
options:

- Low dose cytarabine (LDAC).

- Standard Intensive Chemotherapy (IC) of a 7+3 regimen.

- Best Supportive Care (BSC) only. BSC will be provided to all subjects as per standard
and institutional practice. Subjects randomized to TC will not be allowed to cross over
to guadecitabine. Data will be reviewed by an independent Data Monitoring Committee at
regular intervals, primarily to evaluate safety during study conduct. Randomization will
be stratified by disease category (MDS vs CMML), bone marrow (BM) blasts (BM blasts >10%
vs BM blasts ≤10%), TC option (LDAC vs IC vs BSC), and study center region.

Guadecitabine: 60 mg/m2 given SC daily on Days 1-5 in 28-day cycles (delayed as needed to
allow blood count recovery). Treatment should be given for at least 6 total cycles in the
absence of unacceptable toxicity or disease progression requiring alternative therapy. Beyond
6 cycles, treatment should continue as long as the subject continues to benefit. BSC should
be given according to standard and institutional practice.

Treatment Choice (TC): Before randomization, the investigator will assign each subject to one
of the following TC options:

- Low dose cytarabine (LDAC) given as 20 mg/m2 SC or IV once daily for 14 days in 28-day
cycles (delayed as needed to allow blood count recovery). Treatment should be given for
at least 4 cycles in the absence of disease progression or unacceptable toxicity.

- Standard Intensive Chemotherapy (IC) of a 7+3 regimen: given as cytarabine 100-200
mg/m2/day given as continuous infusion for 7 days and an anthracycline given as per
institutional standard practice such as daunorubicin (45-60 mg/m2/day), or idarubicin
(9-12 mg/m2/day), or mitoxantrone (8-12 mg/m2/day) by intravenous infusion for 3 days.

- Best Supportive Care (BSC) only: given according to standard and institutional practice.
BSC includes, but is not limited to blood transfusions (RBCs or platelets), growth
factors including erythropoiesis stimulating agents (ESA), granulocyte stimulating
factors (GSFs), iron chelating therapy, and broad spectrum antibiotics and/or
antifungals.

Inclusion Criteria:

- Adult subjects ≥18 years of age who are able to understand and comply with study
procedures, and provide written informed consent before any study-specific procedure.

- Cytologically or histologically confirmed diagnosis of MDS or CMML according to the
2008 World Health Organization (WHO) classification.

- Performance status (ECOG) of 0-2.

- Previously treated MDS or CMML, defined as prior treatment with at least one
hypomethylating agent (HMA; azacitidine and/or decitabine) for intermediate or high
risk MDS or CMML whose disease progressed or relapsed as follows:

1. Subject received HMA for at least 6 cycles and was still transfusion dependent
(as defined in 5b below).

2. Subject had disease progression prior to Cycle 6 defined as ≥50% increase in bone
marrow blasts from pretreatment levels to >5%, or ≥2 g/dL reduction of Hgb from
pretreatment levels with transfusion dependence after at least 2 cycles of HMA.

Other prior treatments for MDS such as lenalidomide, cytarabine, intensive chemotherapy,
hydroxyurea, erythropoietin and other growth factors, or hematopoietic cell transplant
(HCT) are allowed.

- Subjects must have either:

1. Bone marrow blasts >5% at randomization, OR

2. Transfusion dependence, defined as having had transfusion (in the setting of
active disease) of 2 or more units of RBC or platelets within 8 weeks prior to
randomization.

- Creatinine clearance or glomerular filtration rate ≥30 mL/min estimated by the
Cockroft-Gault (C-G) or other medically acceptable formulas such as MDRD (Modification
of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology
Collaboration).

- Women of childbearing potential must not be pregnant or breastfeeding and must have a
negative pregnancy test at screening. Women of childbearing potential and men with
female partners of childbearing potential must agree to practice 2 highly effective
contraceptive measures of birth control and must agree not to become pregnant or
father a child while receiving treatment with guadecitabine, LDAC, or IC and for at
least 3 months after completing treatment.

Exclusion criteria:

- Subjects who have been diagnosed as having AML with peripheral blood or bone marrow
blasts of ≥20%.

- Subjects who may still be sensitive to repeated treatment with decitabine or
azacitidine such as subjects who had response to prior decitabine or azacitidine
treatment, but relapsed >6 months after stopping treatment with these agents.

- Prior treatment with guadecitabine.

- Hypersensitivity to decitabine, guadecitabine, or any of their excipients.

- Second malignancy currently requiring active therapy, except breast or prostate cancer
stable on or responding to endocrine therapy.

- Treated with any investigational drug within 2 weeks of the first dose of study
treatment.

- Total serum bilirubin >2.5 ULN (except for subjects with Gilbert's Syndrome for whom
direct bilirubin is <2.5×ULN), or liver cirrhosis or chronic liver disease Child-Pugh
Class B or C.

- Known active HIV, HBV, or HCV infection. Inactive hepatitis carrier status or low
viral hepatitis titer on antivirals is allowed.

- Known significant mental illness or other condition such as active alcohol or other
substance abuse or addiction that, in the opinion of the investigator, predisposes the
subject to high risk of noncompliance with the protocol.

- Refractory congestive heart failure unresponsive to medical treatment, active
infection resistant to all antibiotics, or advanced non-MDS associated pulmonary
disease requiring >2 liters per minute oxygen.
We found this trial at
23
sites
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
267 Lange Beeldekensstraat
Antwerp, 2060
?
mi
from
Antwerp,
Click here to add this to my saved trials
Baltimore, Maryland 20742
(301) 405-1000
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials
Evanston, Illinois 60201
?
mi
from
Evanston, IL
Click here to add this to my saved trials
Fleming Island, Florida 32003
?
mi
from
Fleming Island, FL
Click here to add this to my saved trials
Greenville, South Carolina 29601
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
8111 South Emerson Avenue
Indianapolis, Indiana 46237
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Miami Beach, Florida 33140
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
New York, New York 10021
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Rancho Mirage, CA
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials
101 Nicolls Rd
Stony Brook, New York 11794
(631) 444-4000
Stony Brook University Medical Center Stony Brook Medicine expresses our shared mission of research, clinical...
?
mi
from
Stony Brook, NY
Click here to add this to my saved trials